Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
Fuente:
Wiley Open Access
Saved in:
Bibliographic Details
Main Authors:
Man Sun
,
Dan Zang
,
Jun Chen
Format:
Artículo Open Access
Published:
Wiley
2026
Subjects:
Diabetes, Obesity and Metabolism
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Internet
https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70710
Similar Items
HbA1c ≤ 6.5% in Early Type 2 Diabetes: Threshold, Trajectory, or Marker of Integrated Risk Management?
by: Man Sun, et al.
Published: (2026)
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
by: Andreea Ciudin, et al.
Published: (2026)
Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
by: Chih‐Yuan Wang
Published: (2026)
Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
by: Mai Katsura, et al.
Published: (2026)
The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China
by: Sihua Wang, et al.
Published: (2025)